BioCryst Pharmaceuticals Statistics
Total Valuation
BCRX has a market cap or net worth of $1.42 billion. The enterprise value is $1.89 billion.
Important Dates
The next estimated earnings date is Monday, February 23, 2026, before market open.
| Earnings Date | Feb 23, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BCRX has 210.54 million shares outstanding. The number of shares has increased by 1.84% in one year.
| Current Share Class | 210.54M |
| Shares Outstanding | 210.54M |
| Shares Change (YoY) | +1.84% |
| Shares Change (QoQ) | -0.00% |
| Owned by Insiders (%) | 1.15% |
| Owned by Institutions (%) | 86.06% |
| Float | 180.64M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 22.68 |
| PS Ratio | 2.35 |
| Forward PS | 2.18 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 29.70 |
| P/OCF Ratio | 28.31 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 23.52, with an EV/FCF ratio of 39.52.
| EV / Earnings | n/a |
| EV / Sales | 3.15 |
| EV / EBITDA | 23.52 |
| EV / EBIT | 24.45 |
| EV / FCF | 39.52 |
Financial Position
The company has a current ratio of 1.87
| Current Ratio | 1.87 |
| Quick Ratio | 1.60 |
| Debt / Equity | n/a |
| Debt / EBITDA | 8.27 |
| Debt / FCF | 14.27 |
| Interest Coverage | 0.87 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 10.31% |
| Return on Invested Capital (ROIC) | 14.46% |
| Return on Capital Employed (ROCE) | 30.20% |
| Revenue Per Employee | $1.03M |
| Profits Per Employee | -$15,136 |
| Employee Count | 580 |
| Asset Turnover | 1.28 |
| Inventory Turnover | 29.60 |
Taxes
In the past 12 months, BCRX has paid $2.16 million in taxes.
| Income Tax | 2.16M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -11.30% in the last 52 weeks. The beta is 0.80, so BCRX's price volatility has been lower than the market average.
| Beta (5Y) | 0.80 |
| 52-Week Price Change | -11.30% |
| 50-Day Moving Average | 7.30 |
| 200-Day Moving Average | 8.22 |
| Relative Strength Index (RSI) | 40.24 |
| Average Volume (20 Days) | 4,390,656 |
Short Selling Information
The latest short interest is 39.06 million, so 18.55% of the outstanding shares have been sold short.
| Short Interest | 39.06M |
| Short Previous Month | 36.01M |
| Short % of Shares Out | 18.55% |
| Short % of Float | 21.62% |
| Short Ratio (days to cover) | 10.48 |
Income Statement
In the last 12 months, BCRX had revenue of $599.82 million and -$8.78 million in losses. Loss per share was -$0.05.
| Revenue | 599.82M |
| Gross Profit | 410.45M |
| Operating Income | 77.36M |
| Pretax Income | -6.62M |
| Net Income | -8.78M |
| EBITDA | 80.43M |
| EBIT | 77.36M |
| Loss Per Share | -$0.05 |
Full Income StatementBalance Sheet
The company has $212.87 million in cash and $683.11 million in debt, with a net cash position of -$470.24 million or -$2.23 per share.
| Cash & Cash Equivalents | 212.87M |
| Total Debt | 683.11M |
| Net Cash | -470.24M |
| Net Cash Per Share | -$2.23 |
| Equity (Book Value) | -387.89M |
| Book Value Per Share | -1.84 |
| Working Capital | 165.45M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $50.20 million and capital expenditures -$2.34 million, giving a free cash flow of $47.86 million.
| Operating Cash Flow | 50.20M |
| Capital Expenditures | -2.34M |
| Free Cash Flow | 47.86M |
| FCF Per Share | $0.23 |
Full Cash Flow StatementMargins
Gross margin is 68.43%, with operating and profit margins of 12.90% and -1.46%.
| Gross Margin | 68.43% |
| Operating Margin | 12.90% |
| Pretax Margin | -1.10% |
| Profit Margin | -1.46% |
| EBITDA Margin | 13.41% |
| EBIT Margin | 12.90% |
| FCF Margin | 7.98% |
Dividends & Yields
BCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.84% |
| Shareholder Yield | -1.84% |
| Earnings Yield | -0.62% |
| FCF Yield | 3.37% |
Analyst Forecast
The average price target for BCRX is $20.82, which is 208.44% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $20.82 |
| Price Target Difference | 208.44% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 19.76% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BCRX has an Altman Z-Score of -1.89 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.89 |
| Piotroski F-Score | 6 |
